血浆肌酐测定的实验室间变异及其与估算肾小球滤过率和慢性肾脏病诊断的关系
该研究将53例ICU患者的混合血浆样本送至12个实验室测定肌酐,评估实验室间变异及其对eGFR-EPI和CKD诊断的影响。结果显示肌酐和eGFR-EPI仍存在显著实验室间变异,Jaffe法肌酐值高于酶法,导致eGFR-EPI更低且CKD诊断更频繁。作者认为需进一步改进检测性能以标准化CKD诊断并促进跨实验室纵向肌酐监测。
要点
- 肌酐测定的实验室间变异仍然显著,影响eGFR-EPI和CKD诊断。
- Jaffe法肌酐值平均高于酶法,导致eGFR-EPI更低、CKD诊断更频繁。
- 作者认为需进一步改进检测性能以标准化CKD诊断和跨实验室肌酐监测。
核心结论
- 肌酐测定仍存在显著的实验室间变异,Jaffe法肌酐值高于酶法,导致eGFR-EPI更低且CKD诊断更频繁,需进一步改进检测性能以标准化CKD诊断并促进跨实验室纵向肌酐监测。
研究设计与样本
- 研究纳入53例ICU患者连续2-3天的剩余血浆,混合分装后送至12个不同实验室测定肌酐。
- 对每例患者假定为65岁非黑人女性,计算平均肌酐和CKD-EPI eGFR(eGFR-EPI),以肌酐和eGFR-EPI的极差和SD评估实验室间变异。
- 按检测方法类型和肌酐中位数1.36 mg/dl分层重复分析,并对eGFR-EPI极差包含60 ml/min per 1.73 m2的患者计算eGFR-EPI<60 ml/min per 1.73 m2的实验室百分比。
主要发现
- 肌酐<1.36 mg/dl时,肌酐极差的均值±SD为0.20±0.09 mg/dl,eGFR-EPI极差的均值±SD为14±9 ml/min per 1.73 m2。
- Jaffe法肌酐结果平均较酶法高0.1 mg/dl(肌酐≥1.36 mg/dl)和0.05 mg/dl(肌酐<1.36 mg/dl),两者P<0.001。
- 10例患者的eGFR-EPI极差包含60 ml/min per 1.73 m2,其eGFR-EPI极差中位数为15 ml/min per 1.73 m2。
- CKD(eGFR-EPI<60 ml/min per 1.73 m2)诊断存在显著不一致,使用Jaffe法肌酐的实验室诊断频率高于使用酶法的实验室(60% versus 39%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The tracing of creatinine (Cr) reference materials to isotope dilution mass spectrometry-assigned values was implemented worldwide to reduce interlaboratory variability and improve assay accuracy. The aims of this study were to examine the current extent of interlaboratory variability and its effect on eGFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Leftover plasma from 2-3 consecutive days was obtained from 53 intensive care unit patients with a range of kidney functions. Individual patient samples were pooled and split and sent to 12 different laboratories for Cr measurement. For each patient, the mean Cr and Chronic Kidney Disease Epidemiology Collaboration eGFR (eGFR-EPI), assuming a 65-year-old nonblack woman, were determined. Interlaboratory variability was assessed by the range and SD of Cr and eGFR-EPI. This was repeated after stratifying by assay type and by the median Cr of 1.36 mg/dl. For patients whose eGFR-EPI range included 60 ml/min per 1.73 m2, the percentage of laboratories with eGFR-EPI<60 ml/min per 1.73 m2 was determined. RESULTS: The mean±SD of the Cr and eGFR-EPI ranges were 0.20±0.09 mg/dl and 14±9 ml/min per 1.73 m2 for Cr<1.36 mg/dl. Jaffe Cr results were an average 0.1 mg/dl (Cr≥1.36 mg/dl) and 0.05 mg/dl (Cr<1.36 mg/dl) higher than enzymatic results (P<0.001 for both). Ten patients had an eGFR-EPI range that included 60 ml/min per 1.73 m2. Their median eGFR-EPI range was 15 ml/min per 1.73 m2. There was significant discordance in the diagnosis of CKD (eGFR-EPI<60 ml/min per 1.73 m2), with laboratories using Jaffe Cr methods making the diagnosis more frequently than those using enzymatic Cr methods (60% versus 39%). CONCLUSIONS: Significant interlaboratory variability in Cr measurement still exists. Jaffe assays yield higher Cr values than enzymatic assays, leading to lower eGFR-EPIs and more frequent CKD diagnoses. Further improvements in assay performance are required to standardize patient CKD diagnosis and to facilitate longitudinal Cr monitoring across laboratories.
引用
- Lee E, Collier CP, White CA, et al. Interlaboratory Variability in Plasma Creatinine Measurement and the Relation with Estimated Glomerular Filtration Rate and Chronic Kidney Disease Diagnosis. Clin J Am Soc Nephrol. 2016. PMID: 27827312. doi:10.2215/CJN.05400516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。